| Market Cap | 110.55M | P/E | - | EPS this Y | 48.40% | Ern Qtrly Grth | - |
| Income | -44.77M | Forward P/E | -2.52 | EPS next Y | 100.00% | 50D Avg Chg | -17.00% |
| Sales | 58.2M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -54.00% |
| Dividend | N/A | Price/Book | 2.46 | EPS next 5Y | - | 52W High Chg | -88.00% |
| Recommedations | 2.70 | Quick Ratio | 1.97 | Shares Outstanding | 52.76M | 52W Low Chg | 1.00% |
| Insider Own | 10.92% | ROA | -19.20% | Shares Float | 39.15M | Beta | 1.68 |
| Inst Own | 54.62% | ROE | -109.01% | Shares Shorted/Prior | 3.41M/5.77M | Price | 2.14 |
| Gross Margin | 89.44% | Profit Margin | -76.93% | Avg. Volume | 968,046 | Target Price | 7.15 |
| Oper. Margin | -21.37% | Earnings Date | Oct 30 | Volume | 5,674,527 | Change | -2.28% |
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Umstead John W. V | Chief Financial Offi.. Chief Financial Officer | Jan 03 | Sell | 3.06 | 743 | 2,274 | 130,443 | 01/08/24 |
| Malik Rajesh | Chief Medical Office.. Chief Medical Officer | Jan 03 | Sell | 3.06 | 3,740 | 11,444 | 169,938 | 01/08/24 |
| Perry Andrew | Chief Commercial Off.. Chief Commercial Officer | Jan 03 | Sell | 3.12 | 2,413 | 7,529 | 87,102 | 01/08/24 |
| Bailey John E. (Jack) Jr. | President and CEO President and CEO | Jan 03 | Sell | 3.12 | 11,686 | 36,460 | 489,594 | 01/08/24 |
| Avagliano Mark | Chief Business Offic.. Chief Business Officer | Jan 03 | Sell | 3.06 | 4,081 | 12,488 | 117,834 | 01/08/24 |
| MURDOCK TERRY L | Chief Operating Offi.. Chief Operating Officer | Jan 03 | Sell | 3.06 | 3,740 | 11,444 | 103,638 | 01/08/24 |
| Bailey John E. (Jack) Jr. | President and CEO President and CEO | Jan 02 | Sell | 3.2746 | 32,983 | 108,006 | 400,580 | 01/02/24 |
| Moses Jennifer K. | CFO CFO | Jan 03 | Sell | 5.49 | 2,368 | 13,000 | 57,820 | 01/05/23 |
| MURDOCK TERRY L | Chief Operating Offi.. Chief Operating Officer | Jan 03 | Sell | 5.49 | 2,368 | 13,000 | 36,439 | 01/05/23 |
| Perry Andrew | Chief Commercial Off.. Chief Commercial Officer | Jan 03 | Sell | 5.58 | 820 | 4,576 | 21,300 | 01/05/23 |
| Malik Rajesh | Chief Medical Office.. Chief Medical Officer | Jan 03 | Sell | 5.49 | 2,368 | 13,000 | 102,739 | 01/05/23 |
| Hanson James S. | General Counsel General Counsel | Jan 03 | Sell | 5.49 | 2,368 | 13,000 | 41,087 | 01/05/23 |
| Bailey John E. (Jack) Jr. | President and CEO President and CEO | Jan 03 | Sell | 5.72 | 37,626 | 215,221 | 276,282 | 01/05/23 |
| Velleca Mark A. | Director Director | Oct 18 | Sell | 11.7 | 15,000 | 175,500 | 116,000 | 10/20/22 |
| Velleca Mark A. | Director Director | Oct 18 | Option | 0.39 | 15,000 | 5,850 | 131,000 | 10/20/22 |
| Moses Jennifer K. | CFO CFO | Feb 01 | Option | 3.95 | 2,333 | 9,215 | 37,888 | 02/02/22 |
| Malik Rajesh | Chief Medical Office.. Chief Medical Officer | Feb 01 | Option | 0.30 | 10,000 | 3,000 | 73,855 | 02/02/22 |
| Velleca Mark A. | Director Director | Apr 15 | Option | 0.39 | 30,000 | 11,700 | 51,000 | 04/15/21 |
| Velleca Mark A. | Director Director | Apr 15 | Sell | 24.46 | 30,000 | 733,800 | 41,000 | 04/15/21 |
| Malik Rajesh | Chief Medical Office.. Chief Medical Officer | Jan 22 | Option | 4.17 | 15,000 | 62,550 | 55,200 | 01/22/21 |
| Malik Rajesh | Chief Medical Office.. Chief Medical Officer | Jan 22 | Sell | 20.64 | 15,000 | 309,600 | 40,200 | 01/22/21 |
| Velleca Mark A. | Director Director | Jan 21 | Option | 2.89 | 34,000 | 98,260 | 51,000 | 01/21/21 |
| Velleca Mark A. | Director Director | Jan 21 | Sell | 21.01 | 30,000 | 630,300 | 41,000 | 01/21/21 |
| RUDNICK SETH | Director Director | Dec 23 | Sell | 20.26 | 32,092 | 650,184 | 6,190 | 12/23/20 |
| Velleca Mark A. | President and CEO President and CEO | Dec 17 | Option | 3.72 | 30,000 | 111,600 | 47,000 | 12/17/20 |
| Velleca Mark A. | President and CEO President and CEO | Dec 17 | Sell | 19.53 | 30,000 | 585,900 | 37,000 | 12/17/20 |
| RUDNICK SETH | Director Director | Dec 10 | Sell | 20.17 | 19,480 | 392,912 | 38,282 | 12/10/20 |
| Bailey John E. (Jack) Jr. | Director Director | Nov 13 | Buy | 12.8 | 8,000 | 102,400 | 8,000 | 11/13/20 |